Multidrug-Resistant Profiles in Non-Small Cell Lung Carcinoma Patient-Derived Cells: Implications for Personalized Approaches with Tyrosine Kinase Inhibitors

J Dinić, M Dragoj, S Jovanović Stojanov, A Stepanović… - Cancers, 2024 - mdpi.com
Simple Summary This research investigates the challenge of drug resistance in non-small
cell lung carcinoma (NSCLC) and how certain drugs, namely, tyrosine kinase inhibitors …
相关文章

Multidrug-Resistant Profiles in Non-Small Cell Lung Carcinoma Patient-Derived Cells: Implications for Personalized Approaches with Tyrosine Kinase Inhibitors.

J Dinić, M Dragoj, S Jovanović Stojanov… - …, 2024 - search.ebscohost.com
Abstract Simple Summary: This research investigates the challenge of drug resistance in
non-small cell lung carcinoma (NSCLC) and how certain drugs, namely, tyrosine kinase …

Multidrug-Resistant Profiles in Non-Small Cell Lung Carcinoma Patient-Derived Cells: Implications for Personalized Approaches with Tyrosine Kinase Inhibitors

J Dinić, M Dragoj, SJ Stojanov, A Stepanović… - …, 2024 - pubmed.ncbi.nlm.nih.gov
The impact of tyrosine kinase inhibitors (TKIs) on multidrug resistance (MDR) in non-small
cell lung carcinoma (NSCLC) is a critical aspect of cancer therapy. While TKIs effectively …
[HTML] nih.gov

[HTML][HTML] Multidrug-Resistant Profiles in Non-Small Cell Lung Carcinoma Patient-Derived Cells: Implications for Personalized Approaches with Tyrosine Kinase …

J Dinić, M Dragoj, SJ Stojanov, A Stepanović, E Lupšić… - Cancers, 2024 - ncbi.nlm.nih.gov
The impact of tyrosine kinase inhibitors (TKIs) on multidrug resistance (MDR) in non-small
cell lung carcinoma (NSCLC) is a critical aspect of cancer therapy. While TKIs effectively …